- Pharmaceutical giant Novo Nordisk recently conducted a large-scale study investigating whether weight-loss drug semaglutide could slow Alzheimer’s progression.
- Unfortunately, the study was unsuccessful, and the trial was halted early.
- However, although more research is needed, the results are not entirely negative.
GLP-1 agonists have taken the pharmaceutical world by storm. The active ingredient, semaglutide, is used in the now-famous Ozempic and Wegovy medications for diabetes and weight loss.
Already, these drugs have helped millions of people manage their weight and treat type 2 diabetes.
But could they also help tackle Alzheimer’s disease? Recent clinical trials focused on one of Novo Nordisk’s older diabetes medications called Rybelsus.
Because ongoing efforts to slow the progression of Alzheimer’s have largely been disappointing, even a minor success would provide a rare glimmer of hope for people in the early stages of the condition.
No comments:
Post a Comment